Skip to Main Content
Centers for Disease Control and Prevention link     Centers for Disease Control and Prevention & Smallpox Centers for Disease Control and Prevention link CDC Smallpox Home
Smallpox Vaccination and Adverse Events Training Module - Reactions Links & Site Map Adverse Reactions link Normal Reactions link All Reactions link Site Map link
Side Navigation Menu & Copyright 2002 CDC/HHS Home Page link Smallpox link About the Vaccine link Contraindications link Vaccination Method link Preventing Contact Transmission link Vaccinia Immune Globulin link; Laboratory Testing link Continuing Education link Contact link

Generalized Vaccinia: Management

Frequency link Pathogenesis link Clinical Link Diagnosis link Management link Prevention link General Info link Generalized Vaccinia Menu  
Click here to Zoom History unknown, extensive generalized vaccinia lesions
Back  1 of   Next    Zoom    View All

Click on image to enlarge



Report Adverse Event link Report Adverse Event link
Most instances of generalized vaccinia, particularly if the lesions are few, require no specific therapy. In some cases, with extensive lesions, or in recurrent disease, Vaccinia Immune Globulin (VIG) should be administered in an initial dose of 0.6 ml per kg body weight. Rarely is it necessary to administer more than one course with recurrent disease. 

If an antibody (B-cell) deficient state or another immunologic abnormality is diagnosed, then both VIG therapy for the viral disease and appropriate therapy for the immunologic deficiency must be decided in consultation with an immunologist.




Accidental Administration link Inadvertent Inoculation link Bacterial Infection link Congenital Vaccinia link Eczema Vaccinatum link Encephalitis link Erythema Multiforme link Generalized Vaccinia link Normal Primary link Normal Variants link Progressive Vaccinia link Vaccinia Keratitis link Revaccination link All Reactions links